Evidence map›Paper›PMID 33414788›Full record

ArticleFrontiers in immunology2020

A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza.

Tatsuya Yamazaki, Mrityunjoy Biswas, Kouyu Kosugi, Maria Nagashima, Masanori Inui, Susumu Tomono, Hidekazu Takagi, Isao Ichimonji, Fumiaki Nagaoka, Akira Ainai and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tatsuya YamazakiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Mrityunjoy BiswasDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Kouyu KosugiDepartment of Biological Science and Technology, Tokyo University of Science, Tokyo, Japan.
Maria NagashimaDepartment of Biological Science and Technology, Tokyo University of Science, Tokyo, Japan.
Masanori InuiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Susumu TomonoDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Hidekazu TakagiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Isao IchimonjiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Fumiaki NagaokaDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Akira AinaiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Hideki HasegawaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Joe ChibaDepartment of Biological Science and Technology, Tokyo University of Science, Tokyo, Japan.
Sachiko Akashi-TakamuraDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi, Japan.
Aichi Medical University · JPTokyo University of Science · JPNational Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen

Indexed as

Genetic VectorsGene Transfer TechniquesAdjuvants, ImmunologicAnimalsAntibodies, MonoclonalAntigens, CDAntigens, SurfaceB-LymphocytesCell MembraneCell ProliferationCoculture TechniquesHEK293 CellsHemagglutinin Glycoproteins, Influenza VirusHumansHybridomasImmunizationAdjuvants, ImmunologicAntibodies, MonoclonalAntigens, CDAntigens, SurfaceH1N1 virus hemagglutininHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesLy78 protein, mouseLy86 protein, mouseMembrane GlycoproteinsReceptors, IgGVaccines, DNAadjuvantagonistic antibodyantibody gene-vector deliverycell membraneDNA immunizationinfluenzaRP105targeting antigen to B cells

Identifiers

PMID33414788
PMCPMC7783388
OpenAlexW3118006551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.